论文部分内容阅读
经皮穿刺冠状动脉成形术(PTCA)对于治疗稳定型和不稳定型心绞痛已是一个有效的治疗方法。从最初的单支病变到多支病变及溶栓治疗后残留病变都可以采用PTCA治疗。对于梗阻血管未用链激酶治疗,也已采用机械性扩张而再通。 PTCA一个没能解决的问题是血管再狭窄,约有17-44％病例在PTCA术后六个月内发生再狭窄。其中一个因素是球囊的大小,另一个可能是扩张的时间。延长扩张时间可以增加成功率、降低再狭窄率。延长扩张时间可以用硝酸甘油和硝苯吡啶,但是硝酸甘油治疗并不是对所有病人有效。为此,作者研制了一种新型导管,能够在PTCA过程中进行连续灌注,以便延长扩张时间(称CPC
Percutaneous transluminal coronary angioplasty (PTCA) is an effective treatment for stable and unstable angina. From the initial single-vessel disease to multi-vessel disease and thrombolytic therapy residual disease can be treated with PTCA. For the obstruction of blood vessels not treated with streptokinase, has also been used to recruit mechanical expansion. One of the problems that PTCA can not solve is restenosis. About 17-44% of cases have restenosis within six months after PTCA. One of the factors is the size of the balloon and the other may be the time of expansion. Prolonging the time of expansion can increase the success rate and reduce the rate of restenosis. Nitroglycerine and nifedipine can be used to prolong the dilatation time, but nitroglycerin is not effective in all patients. To this end, the authors developed a new catheter that allows continuous perfusion during PTCA to extend the dilation time (referred to as CPC